Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luseogliflozin in Type 2 Diabetes Mellitus Patients on Moderate Dose Insulin
NCT07876258Phase 3Completed
- Start
- May 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
A Phase 3 trial of luseogliflozin in type 2 diabetes mellitus (T2DM). Started May 2022; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07876258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876258.